Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Seres Therapeutics Inc (MCRB)

Seres Therapeutics Inc (MCRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 96,057
  • Shares Outstanding, K 151,009
  • Annual Sales, $ 126,330 K
  • Annual Income, $ -113,720 K
  • 60-Month Beta 2.23
  • Price/Sales 0.74
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MCRB with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.90
  • Most Recent Earnings $-0.32 on 03/05/24
  • Latest Earnings Date 05/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 652.30% ( +408.36%)
  • Historical Volatility 63.55%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 652.30% on 04/17/24
  • IV Low 27.12% on 01/11/24
  • Put/Call Vol Ratio 0.04
  • Today's Volume 24
  • Volume Avg (30-Day) 507
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 41,501
  • Open Int (30-Day) 40,209

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.36
  • Number of Estimates 4
  • High Estimate -0.27
  • Low Estimate -0.43
  • Prior Year -0.57
  • Growth Rate Est. (year over year) +36.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6020 +4.20%
on 04/17/24
0.8539 -26.54%
on 03/19/24
-0.1584 (-20.16%)
since 03/15/24
3-Month
0.6020 +4.20%
on 04/17/24
1.3300 -52.83%
on 01/18/24
-0.6627 (-51.37%)
since 01/17/24
52-Week
0.6020 +4.20%
on 04/17/24
6.8700 -90.87%
on 04/18/23
-5.9227 (-90.42%)
since 04/17/23

Most Recent Stories

More News
Seres Therapeutics: Q3 Earnings Snapshot

Seres Therapeutics: Q3 Earnings Snapshot

MCRB : 0.6273 (-1.38%)
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 16.82 (-3.00%)
FHTX : 5.78 (-4.15%)
MRNA : 103.44 (-0.34%)
OMGA : 2.56 (+6.02%)
SANA : 8.26 (-1.78%)
MCRB : 0.6273 (-1.38%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFoundâ„¢ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 16.82 (-3.00%)
FHTX : 5.78 (-4.15%)
MRNA : 103.44 (-0.34%)
OMGA : 2.56 (+6.02%)
SANA : 8.26 (-1.78%)
MCRB : 0.6273 (-1.38%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 16.82 (-3.00%)
FHTX : 5.78 (-4.15%)
MRNA : 103.44 (-0.34%)
OMGA : 2.56 (+6.02%)
SANA : 8.26 (-1.78%)
MCRB : 0.6273 (-1.38%)
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business...

DNLI : 16.82 (-3.00%)
FHTX : 5.78 (-4.15%)
MRNA : 103.44 (-0.34%)
OMGA : 2.56 (+6.02%)
SANA : 8.26 (-1.78%)
MCRB : 0.6273 (-1.38%)
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as...

DNLI : 16.82 (-3.00%)
FHTX : 5.78 (-4.15%)
MRNA : 103.44 (-0.34%)
OMGA : 2.56 (+6.02%)
SANA : 8.26 (-1.78%)
MCRB : 0.6273 (-1.38%)
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act...

DNLI : 16.82 (-3.00%)
FHTX : 5.78 (-4.15%)
MRNA : 103.44 (-0.34%)
OMGA : 2.56 (+6.02%)
SANA : 8.26 (-1.78%)
MCRB : 0.6273 (-1.38%)
Seres Therapeutics: Q2 Earnings Snapshot

Seres Therapeutics: Q2 Earnings Snapshot

MCRB : 0.6273 (-1.38%)
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 0% and 126.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

MCRB : 0.6273 (-1.38%)
SRNEQ : 0.0300 (+3.45%)
Seres Therapeutics: Q1 Earnings Snapshot

Seres Therapeutics: Q1 Earnings Snapshot

MCRB : 0.6273 (-1.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 0.7072
2nd Resistance Point 0.6811
1st Resistance Point 0.6542
Last Price 0.6273
1st Support Level 0.6012
2nd Support Level 0.5751
3rd Support Level 0.5482

See More

52-Week High 6.8700
Fibonacci 61.8% 4.4756
Fibonacci 50% 3.7360
Fibonacci 38.2% 2.9964
Last Price 0.6273
52-Week Low 0.6020

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar